Actovegin in the management of patients after ischemic stroke: A systematic review.
la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D · 2022 · PloS one
What does this source report?
The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
- Population and setting
- Five controlled studies after ischemic stroke; one randomized trial and four observational studies
- Evidence type
- Review
- Preparation
- Deproteinized calf-blood derivative
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D. Actovegin in the management of patients after ischemic stroke: A systematic review. PloS one 2022.
Molekul research summary: https://molekul.io/research/actv-35771887. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry